Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.69 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417340 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL31381152 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL3728919 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL31381151 | 0.97 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL122604 | 0.97 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL19821335 | 0.97 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL6811206 | 0.97 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL18092159 | 0.92 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL23834444 | 0.92 | NR5A2 (0.83) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT | |
| SCHEMBL10498201 | 0.92 | NR5A2 (0.83) | ALDH1A1SMN1; SMN2NR5A2NR5A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025552-A1 | Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists | CHILDREN`S MEDICAL CENTER CORPORATION | 2025-01-23 | — | — | US | claimed |
| US-20240415957-A1 | PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS | CHILDREN`S MEDICAL CENTER CORPORATION | 2024-12-19 | — | — | US | claimed |
| US-20240398865-A1 | TUMOR AVATAR VACCINE COMPOSITIONS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2024-12-05 | — | — | US | claimed |
| US-12070499-B2 | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-08-27 | — | — | US | claimed |
| US-12053522-B2 | Pro-inflammatory and anti-cancer functions of toll-like receptor 4 antagonists | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-08-06 | — | — | US | claimed |
| US-20240122975-A1 | IN VITRO METHODS AND COMPOSITIONS FOR ENHANCING THE ACTIVATION OF DENDRITIC CELLS AND T CELLS, AND FOR INDUCING A TH-1 IMMUNE RESPONSE | NORTHWEST BIOTHERAPEUTICS, INC. (US) | 2024-04-18 | — | — | US | claimed |
| CN-114894910-B | New application of 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine detection reagent | 重庆医科大学附属第一医院 | 2023-10-20 | — | — | CN | claimed |
| CN-116209431-A | Organ preservation and/or perfusion solution | 西维沃医疗科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| US-20230053338-A1 | PRO-INFLAMMATORY AND ANTI-CANCER FUNCTIONS OF TOLL-LIKE RECEPTOR 4 ANTAGONISTS | CHILDREN'S MEDICAL CENTER CORPORATION | 2023-02-23 | — | — | US | claimed |
| US-20230042429-A1 | Pro-Inflammatory and Adjuvant Functions of Toll-Like Receptor 4 Antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-09 | — | — | US | claimed |
| US-11400153-B2 | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| US-11351250-B2 | Pro-inflammatory and anti-cancer functions of toll-like receptor 4 antagonists | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-06-07 | — | — | US | claimed |
| WO-2018067302-A2 | THERAPEUTIC EFFECTS OF CELLULAR DELIVERY OF SMALL MOLECULES AND MACROMOLECULES WITH LIPOSOMAL SPHERICAL NUCLEIC ACIDS | NORTH WESTERN UNIVERSITY (US) | 2018-04-12 | — | — | WO | claimed |
| EP-2142199-B1 | A PROCESS TO ACTIVATE EXTRACTS DERIVED FROM LIVING ORGANISMS USING LONG WAVE UV IRRADIATION AND COMPOSITIONS COMPRISING SAID ACTIVATED EXTRACT | UNIV WIEN MED (AT) | 2015-08-05 | — | — | EP | claimed |
| US-20140161733-A1 | BIOMARKER-TARGETING CONTRAST AGENTS AND THEIR USE IN MAGNETIC RESONANCE IMAGING FOR DETECTION OF ATHEROSCLEROTIC PLAQUE | LUNA INNOVATIONS INCORPORATED (US) | 2014-06-12 | — | — | US | claimed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | L.E.A.F. HOLDINGS GROUP LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20040047861-A1 | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof | HAMBURGER STIFTUNG ZUR FOERDERUNG VON WISSENSCHAFT UND KULTUR C/O MERA GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| US-20040028749-A1 | Treating inflammation and associated complications | MINNESOTA, REGENTS OF THE UNIVERSITY OF | 2004-02-12 | — | — | US | disclosed |
| US-20030229015-A1 | Orally administered peptides synergize statin activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | CPT2, SOD1, TFRC | ALDH1A1 3466/4885SMN1; SMN2 418/4885NR5A2 3415/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | ALDH1A1 4668/4885SMN1; SMN2 4549/4885NR5A2 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.